Celecoxib News and Research

RSS

Drugs formerly contraindicated for inflammatory bowel disease prove beneficial for pain relief

According to two studies published in the American Gastroenterological Association (AGA) journal Clinical Gastroenterology and Hepatology, prescription painkillers are effective in easing the pain of patients with dormant inflammatory bowel disease (IBD) and are not likely to cause symptom flare-ups in IBD patients in remissions

12 Feb 2006

Regular use of COX-2 inhibitors reduces breast cancer risk

A case-control study published today in the open access journal BMC Cancer observed that daily use of selective COX-2 inhibitors, including celecoxib (Celebrex) and rofecoxib (Vioxx), was associated with a 71% reduction in the risk of breast cancer.

2 Feb 2006

COX-2 inhibitors may not be as safe as originally thought

There is no evidence to back up claims that the new generation of anti-inflammatory drugs (COX-2 inhibitors) are less harmful to the stomach lining than many traditional anti-inflammatory drugs, concludes a study in the British Medical Journal.

7 Dec 2005

It's true! study confirms that Glucosamine and Chondroitin relieve arthritis pain

The millions of Osteoarthritis sufferers in the world will welcome the good news that a new study has confirmed that the dietary supplements glucosamine and chondroitin provide pain relief.

15 Nov 2005

Taking either COX-2 inhibitors or NSAIDs after a heart attack increases the risk of death

In recent years, evidence has shown that patients treated with selective cyclo-oxygenase-2 (COX-2) inhibitors are at increased risk of heart attack and death. COX-2 inhibitors are used primarily to treat pain and arthritis in patients at risk of gastrointestinal bleeding.

13 Nov 2005

Zyflamend shows promise in the early treatment of prostate cancer

Data from the Columbia University Department of Urology demonstrates that Zyflamend, a unique herbal extract preparation, suppresses the growth of prostate cancer cells and induces prostate cancer cells to self-destruct via a process called "apoptosis."

13 Nov 2005

Introgen's INGN 241 combined with Celebrex kills breast cancer cells

Introgen Therapeutics, Inc. today reported the publication of preclinical data demonstrating that INGN 241 works synergistically with celecoxib (Celebrex) marketed by Pfizer to inhibit the growth and increase apoptosis (cell death) of breast cancer cells.

8 Nov 2005

Low-dose aspirin might prevent the cardiovascular damage known to arise from use of the painkiller rofecoxib (Vioxx)

Their findings that a chemical imbalance might underlie such damage could also lead to the development of anti-inflammatory drugs without the adverse side effects, the researchers said.

20 Sep 2005

Double whammy of vitamin D and anti-inflammatory zaps prostate cancer cells

Scientists from Stanford University say they have discovered that vitamin D, known as the "sunshine vitamin,"can limit the growth of prostate cancer cells when combined with non-steroidal anti-inflammatory drugs.

6 Sep 2005

Low doses of the active form of vitamin D and non-steroidal anti-inflammatory drugs form one-two punch against prostate cancer cells

Low doses of the active form of vitamin D and non-steroidal anti-inflammatory drugs, taken in combination, have been shown to act as a powerful one-two punch that knocks down the growth of prostate cancer cells.

1 Sep 2005

Relative of the celebrated COX-2 inhibitor celecoxib is tough tumor fighter

A close structural relative of the celebrated COX-2 inhibitor celecoxib (brand name: Celebrex) is a potent tumor fighter, able to wipe out tumor cells that are resistant to conventional chemotherapies, according to an interdisciplinary team of researchers from the University of Southern California.

29 Aug 2005

Ibruprofen and other commonly used painkillers for treating inflammation may increase the risk of heart attack

Patients should not stop taking the drugs involved - non-steroidal anti-inflammatory drugs (NSAIDS) - but further investigation into these treatments is needed, say the authors.

10 Jun 2005

Commonly used painkillers for treating inflammation may increase the risk of heart attack

Patients should not stop taking the drugs involved - non-steroidal anti-inflammatory drugs (NSAIDS) - but further investigation into these treatments is needed, say the authors.

9 Jun 2005

Study suggests continuous NSAID treatment more effectively reduces X-Ray progression than intermittent treatment

A widely under-recognized form of arthritis, ankylosing spondylitis (AS) is a chronic, progressive disease targeting the spine.

2 Jun 2005

Blocking the COX-1 enzyme might be the answer in ovarian cancer treatment

Researchers at Vanderbilt University Medical Center in a new report say that blocking the COX-1 enzyme - not COX-2 - might lead to a way to prevent and treat the most common and fatal form of ovarian cancer.

2 May 2005

Blocking the COX-1 enzyme might prevent and treat the most common and fatal form of ovarian cancer

Blocking the COX-1 enzyme - not COX-2 - might lead to a way to prevent and treat the most common and fatal form of ovarian cancer, researchers at Vanderbilt University Medical Center reported this week.

1 May 2005

Animi-3 may offer hope for rheumatoid arthritis

Animi-3, a prescription medication from PBM Pharmaceuticals, Inc., contains ingredients that may have a beneficial, protective effect in inflammatory diseases such as rheumatoid arthritis (RA).

7 Apr 2005

Patch therapy provides similar pain relief as oral medications for patients with osteoarthritis (OA) knee pain

Researchers from the Altoona Arthritis and Osteoporosis Center have announced that data presented at the 24th Annual Scientific Meeting of the American Pain Society suggest that patch therapy provides similar pain relief as oral medications for patients with osteoarthritis (OA) knee pain.

3 Apr 2005

International expert group discusses alternatives to COX-2 inhibitors

International group of pain specialists meets to develop recommendations for the treatment of chronic moderate-to-severe pain in the wake of the global withdrawal of rofecoxib (Vioxx) and concerns regarding use of other COX-2 inhibitors.

7 Mar 2005

Celebrex provides a two pronged attack against prostate cancer

Celecoxib, a selective COX-2 inhibitor with promising anti-cancer properties, has now been found to attack prostate cancer cells in a second way that differs from Vioxx (rofecoxib), another anti-inflammatory drug that also inhibits COX-2.

1 Mar 2005